|
TUMOUR GROUP/SITE |
TRIAL SUMMARY |
OPENING DATE |
BREAST - Adjuvant
|
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE) BCCA CODE: BRTDCARE |
Oct 2011 |
|
A Phase III Randomized Trial of Metformin versus Placebo On Recurrence and Survival In early stage Breast Cancer
BCCA CODE: BRMA32 |
Oct 2010 |
|
A Randomized Phase III Study of Radiation Doses and Fractionization Schedules for Ductal Carcinoma in Situ (DCIS) of the Breast
BCCA CODE: BRMA33 |
Oct 2009 |
|
What is the variability of tumor bed shifts among multiple observers when 3D Ultrasound is used for breast image guided radiation therapy? * Clinical Research at VIC |
Oct 2009 |
A Randomized Anastrozole Exercise Trial (RAE trial)
BCCA CODE: BRTANEX |
June 2008 |
|
A Phase II Prospective Evaluation of the Informational Content of Setup Verification Images for Patients Receiving Breast Radiation Therapy Tangentially With or Without Supraclavicular Treatment (Catalyst) * Clinical Research at VIC |
June 2008 |
|
A Randomized Trial of Accelerated Partial Breast Irradiation: The Canadian R.A.P.I.D. Trial * Clinical Research at VIC |
April 2006 |
BREAST - Metastatic
|
Gene Expression Changes During the Development of Hormone Resistance In Metastatic Breast Cancer * Clinical Research at VIC |
July 2003 |
|
Top |
|
| CENTRAL NERVOUS SYSTEM (CNS) |
A Randomized Phase III Study of Temozolomide and Short-Course Radiation vs Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
BCCA CODE: CNCE6RT |
Oct 2007 |
|
Top |
| GASTROINTESTINAL (GI) |
|
|
|
Top |
GENITOURINARY (GU) - Prostate
|
A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
BCCA CODE: GUTPREVAIL |
March 2011 |
|
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer
BCCA CODE: GUTCUSDOC |
Jan 2011 |
|
RADICALS - Radiotherapy and Androgen Deprivation Therapy In Combination after Local Surgery. A randomised controlled trial in prostate cancer |
Apr 2010 |
| Investigating the Immune Response to Prostate Cancer in Subjects Undergoing Standard Treatment * Deeley Research Centre |
2005 |
GENITOURINARY (GU) - Kidney
|
|
|
| GENITOURINARY (GU) - Bladder |
|
|
|
Top |
| GYNECOLOGIC - Ovary |
IROC - The Immune Response to Ovarian Cancer * Deeley Research Centre |
Aug 2007 |
|
Top |
LUNG - Adjuvant
|
A Phase 3, Randomized, Double-Blinded,Placebo-Controlled Study Of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib In Previously Treated Subjects With Locally Advanced Or Metastatic, Non-Squamous, Non–Smallcell Lung Cancer (Nsclc) BCCA CODE: LUTARQER |
Jan 2012 |
|
A Randomized Controlled Trial Of Systemic And Topical Treatments For Rash Secondary To Erlotinib In Advanced Stage IIIB Or IV Non-Small Cell Lung Cancer
BCCA CODE: LUTRAERL |
June 2009 |
|
Top |
LYMPHOMA
|
Phase II Trial Investigating Tailoring First-Line Therapy for Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Result
BCCA CODE: LYTPET |
Oct 2006 |
| IROL - The Immune Response to Lymphoma (BCCF) * Deeley Research Centre |
|
|
Top |
| MELANOMA |
A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma (IND.202) BCCA CODE: SMIND202 |
Sept 2011 |
|
Top |
| SARCOMA |
|
|
|
Top |
| SUPPORTIVE / PALLIATIVE CARE |
|
|
|
Top |
| SYMPTOM MANAGMENT |
A Randomized, Double-Blind, Placebo-Controlled Crossover Comparison of Sennosides and Polyethylene Glycol for Constipation in Palliative Care Outpatients with Advanced Cancer.
BCCA CODE: SCTPEGSEN |
|
|
Top |
| MULTI SITE |
PREDICT - Personal REsponse Determinants in Cancer Therapy - (MSFHR) * Clinical Research at VIC |
Jan 2006 |
|
Top |